Skip to main content
. 2023 Nov 30;11(11):e007339. doi: 10.1136/jitc-2023-007339

Figure 4.

Figure 4

Assessment of TMB status between tissue-based and blood-based assays by disease ontology, for (A) samples with MSAF≥1% and (B) samples with MSAF≥1% to <10% versus ≥10%. Number of sample pairs is shown inside each bar. aData are shown for the top five most frequent disease ontologies among samples with MSAF≥1%. CUP, carcinoma of unknown primary; MSAF, maximum somatic allele frequency; PPA, positive percentage agreement; TMB, tumor mutational burden.